ArticleFrontiers in pharmacology2025
Case Report: Micronized purified flavonoid fraction [Daflon]-induced bradycardia.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research progress on the metabolic fate of citrus flavonoids and strategies to improve bioavailability.Food chemistry: X · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Flavonoids are oral venoactive drugs frequently prescribed to relieve the symptoms of chronic venous disorders. Micronized purified flavonoid fraction (MPFF, commercial Daflon 1000 mg) is a preparation that contains mainly diosmin and a small fraction of hesperidin. Both active ingredients are flavonoids, known for their anti-inflammatory and antioxidant properties. Objective: Whether the MPFF can alter hemodynamic behavior was examined. Methods: Daflon 1,000 mg was administered for 60 days, and the hemodynamic parameters were measured during the circadian cycle. Results: There were no significant differences for systolic blood pressure (100.1 ± 10.6 mmHg vs. 104.8 ± 7.7 mmHg) or diastolic blood pressure (73.8 ± 3.1 mmHg vs. 76.4 ± 6.6 mmHg) before and after MPFF intake, respectively (p > 0.05). However, in sharp contrast, the heart rate reduced significantly after intake of MPFF (88.8 ± 10.5 bpm vs. 79.3 ± 9.7 bpm; p < 0.05). The mean blood pressure was negatively correlated with the heart rate (HR) in the afternoon (r = -0.450, p = 0.016). During this period, there was a decrease in vein inflammation and varicosity, as shown by magnetic resonance imaging. Conclusion: We reported a new effect of MPFF as an attenuator of the heart rate. Because venous insufficiency decreased during the observed drug administration period, further studies are needed to examine whether the ability of diosmin and hesperidin to reduce vein disorders is directly linked to their action on heart rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.